

DevsHealth and FNDR unveil first fully Al-designed antiviral compound targeting dengue

10 July 2025 | News

DHFLV_003B is now undergoing optimisation and advanced preclinical validation



DevsHealth, a European company specialised in artificial intelligence (AI)-driven drug discovery, and the Foundation for Neglected Disease Research (FNDR), based in Bengaluru, have announced the identification of DHFLV_003B, the first antiviral compound against dengue designed entirely through AI with the DevsHealth's proprietary computational platform.

Unlike traditional processes, DHFLV_003B was designed from scratch in silico using DevsHealth OS, an advanced Al platform that generates, simulates and selects potential therapeutic molecules. This computational approach has reduced research timelines from years to months, enhancing both precision and resource efficiency.

DHFLV_003B is now undergoing optimisation and advanced preclinical validation. Next steps include animal model efficacy studies and preparation for future clinical trials. DevsHealth and FNDR aim to translate this innovation into patient impact swiftly, setting a new standard in global antiviral development.

DevsHealth and FNDR have initiated an optimisation programme aimed at enhancing DHFLV_003B's antiviral potency and expanding its spectrum to other flaviviruses such as Zika and West Nile virus.